Healthcare Industry News: heart valve
News Release - May 4, 2007
ATS 3f Aortic Bioprosthesis Offers Unique Approach to Enhanced DurabilityMINNEAPOLIS, May 4 (HSMN NewsFeed) -- ATS Medical, Inc. (Nasdaq: ATSI ) today acknowledged the positive clinical results presented by noted cardiologist, Dr. Xu Yu Jin from the Department of Surgery at the John Radcliffe Hospital in Oxford, U.K.
Dr. Jin's presentation at the recent Advanced Cardiac Techniques in Surgery conference sponsored by the Lenox Hill Heart and Vascular Institute of New York was entitled "Implantation Technique and Implication of 3f Stentless Valve Design for Aortic Root Geometry." In a prospective echocardiographic study of 150 patients, the author studied aortic root dimensions in patients receiving the ATS 3f® Aortic Bioprosthesis with its single suture line/3 tab fixation, stentless valves implanted with conventional double suture line techniques and native valve aortic roots. Among the conclusions, Dr. Jin reported that valves implanted with double suture-line techniques led to significantly smaller aortic sinus diameter and formed tubular aortic root geometry. The ATS 3f valve with no direct sutures in the aortic sinus fully preserved the native aortic root geometry without compromising valve hemodynamics or left ventricular mass.
James L. Cox, MD, Emeritus Evarts A. Graham Professor of Surgery, Washington University School of Medicine, St. Louis, Missouri, and principal in the development of the ATS 3f® Aortic Bioprosthesis offered his comments on Dr. Jin's observations. "The original objective of the ATS 3f, form follows function, valve was to reproduce the function, not the form of the normal native aortic valve. This approach dictates that if the function is accurately reproduced, the normal form of the aortic valve will slavishly follow. Dr. Jin's study documents that the normal form of the aortic root is best preserved/reestablished by implantation of the ATS 3f valve, confirming the accuracy of the original concept. Preserving the aortic root in its natural form is but one more indication that the ATS 3f aortic valve prosthesis is fundamentally different from all previous valve prostheses and strongly suggests that its longevity will be superior to all previous artificial tissue valves," noted Dr. Cox.
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, is headquartered in Minneapolis, Minnesota. More than 135,000 ATS Open Pivot® heart valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3F® brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(TM) annuloplasty products for heart valve repair, SurgiFrost® and FrostByte(TM) products for surgical cryoablation of cardiac arrhythmias, RTI-Cardiovascular for allograft tissue services, and the development of PARSUS blood filtration technology. The ATS Medical web site is http://www.atsmedical.com.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3F Therapeutics, regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2006.
Source: ATS Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.